NEW HAVEN, CT--(Marketwire - March 25, 2013) - Immunovative Inc. (OTCQB: IMUN) or ("the Company") today announced that Marvanal Inc. ("Marvanal") is currently an approved vendor for the State of Connecticut public school food lunch program ("CT Lunch Program"). Marvanal's lactose-free dairy products are authorized for the 2012-2013 CT Lunch Program; Marvanal is currently developing a comprehensive line of dairy products utilizing a specific food-protein concentration-based technology. On March 13, 2013, the Company signed a Memorandum of Understanding ("MOU") with Marvanal to acquire the exclusive marketing rights within the State of New York ("NY State") for Marvanal's lactose-free, dairy product line.
IMUN CEO Seth M. Shaw commented, "It is important that Marvanal has achieved approved vendor status for the CT Lunch Program. The Company is most interested in the potential business opportunity that exists in selling Marvanal's product line, once completed, to the NY State public school system. Both management teams are working through the due diligence process and fully expect to progress to a definitive license agreement for the State of New York."
Marvanal President Mr. Alex L. Bozzi IV stated, "We are very excited about the prospects of selling our products to the public school system of NY State and are confident that both parties will enter into a definitive agreement. The management team of Immunovative has a well thought out strategy to market our products to NY State public schools and potentially provide students in that state with a nutritious, tasty, virtually fat-free dairy lunch option."
About Immunovative Inc.
Immunovative's focus is to evaluate potential opportunities in the biotechnology and/or medical device industry, however it will consider other potential business sectors if deemed in the best interest of shareholders. Additionally on March 4, 2013, the Company announced that it filed for a name and symbol change, such that the Company has changed its name to Tauriga Sciences Inc. and is awaiting its new trading symbol.
About Marvanal Inc.
Founded in 2007, Marvanal Inc. is headquartered in Hamden, Connecticut and operates as a food protein based technology company focused on the elimination of fat from dairy products, thereby lowering the calories without sacrificing any nutritional benefits. Marvanal's main product lines include but are not limited to, the following foods: raviolis, manicotti, enchiladas, and macaroni & cheese. Marvanal is in the process of securing intellectual property and is working diligently to launch its commercial dairy product lines by the summer of 2013.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.